Oncology, Immunology & Precision Biologics
14 Therapeutic ProgramsDe novo design of high-affinity biologics, bispecific antibodies, and allosteric small-molecule inhibitors targeting refractory solid tumors and autoimmune pathways. Candidates are evaluated for target selectivity,epitope stability, and synthetic tractability.